TNF-blocking therapies: An alternative mode of action?

Trends in Immunology

Volumn 26, Issue 10, 2005, Pages 518-522

  Choo Kang, Brian S W ^a   Hutchison, Sharon ^a   Nickdel, Mohammad B ^a   Bundick, Robert V ^b   Leishman, Andrew J ^b   Brewer, James M ^a   McInnes, Iain B ^a   Garside, Paul ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYTOKINE; ETANERCEPT; IMMUNOLOGIC AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG INDICATION; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; LYMPH NODE; LYMPH NODE HYPERPLASIA; MAST CELL; NONHUMAN; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS;

EID: 24744459628     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2005.07.007     Document Type: Article

References (49)

1. D.G. Stokes, and J.M. Kremer Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis Semin. Arthritis Rheum. 33 2003 1 18
2. Mpofu, S. et al. (2004) Anti-TNF-α therapies: they are all the same (aren't they?). Rheumatology (Oxford)
3. B.E. Sands Why do anti-tumor necrosis factor antibodies work in Crohn's disease? Rev. Gastroenterol. Disord. 4 Suppl. 3 2004 S10 S17
4. M.C. Hochberg The benefit/risk profile of TNF-blocking agents: findings of a consensus panel Semin. Arthritis Rheum. 34 2005 819 836
5. K. Pfeffer Biological functions of tumor necrosis factor cytokines and their receptors Cytokine Growth Factor Rev. 14 2003 185 191
6. M.J. Eck, and S.R. Sprang The structure of tumor necrosis factor-α at 2.6 A resolution. Implications for receptor binding J. Biol. Chem. 264 1989 17595 17605
7. R.A. Black A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells Nature 385 1997 729 733
8. F. Bazzoni, and B. Beutler The tumor necrosis factor ligand and receptor families N. Engl. J. Med. 334 1996 1717 1725
9. J. Rothe Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes Nature 364 1993 798 802
10. K.F. Chan Signaling by the TNF receptor superfamily and T cell homeostasis Immunity 13 2000 419 422
11. S.L. Erickson Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice Nature 372 1994 560 563
12. I.K. Campbell Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis Immunol. Cell Biol. 81 2003 354 366
13. E.H. Choy, and G.S. Panayi Cytokine pathways and joint inflammation in rheumatoid arthritis N. Engl. J. Med. 344 2001 907 916
14. D.M. Butler Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-α antibody with the interleukin-1 receptor antagonist Eur. Cytokine Netw. 6 1995 225 230
15. F.S. Di Giovine Tumour necrosis factor in synovial exudates Ann. Rheum. Dis. 47 1988 768 772
16. R.N. Maini Beneficial effects of tumour necrosis factor-α (TNF-α) blockade in rheumatoid arthritis (RA) Clin. Exp. Immunol. 101 1995 207 212
17. J. Keffer Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis EMBO J. 10 1991 4025 4031
18. R.O. Williams Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis Proc. Natl. Acad. Sci. U. S. A. 89 1992 9784 9788
19. N.J. Olsen, and C.M. Stein New drugs for rheumatoid arthritis N. Engl. J. Med. 350 2004 2167 2179
20. P.C. Taylor Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis Arthritis Rheum. 43 2000 38 47
21. P.P. Tak Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis Arthritis Rheum. 39 1996 1077 1081
22. E.M. Paleolog Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis Arthritis Rheum. 41 1998 1258 1265
23. M.R. Ehrenstein Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy J. Exp. Med. 200 2004 277 285
24. A. Lugering Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway Gastroenterology 121 2001 1145 1157
25. T. ten Hove Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease Gut 50 2002 206 211
26. A.I. Catrina Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report Arthritis Rheum. 52 2005 61 72
27. M.A. Quinn Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial Arthritis Rheum. 52 2005 27 35
28. D.M. Catron Visualizing the first 50 hr of the primary immune response to a soluble antigen Immunity 21 2004 341 347
29. + T and CCR7 B and T lymphocytes in thyroid autoimmune diseases J. Immunol. 170 2003 6320 6328
30. S.C. Bischoff Mast cells are an important cellular source of tumour necrosis factor α in human intestinal tissue Gut 44 1999 643 652
31. J.R. Gordon, and S.J. Galli Release of both preformed and newly synthesized tumor necrosis factor α (TNF-α)/cachectin by mouse mast cells stimulated via the FcεRI. A mechanism for the sustained action of mast cell-derived TNF-α during IgE-dependent biological responses J. Exp. Med. 174 1991 103 107
32. B. Echtenacher Critical protective role of mast cells in a model of acute septic peritonitis Nature 381 1996 75 77
33. R. Malaviya Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α Nature 381 1996 77 80
34. T. Biedermann Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2 J. Exp. Med. 192 2000 1441 1452
35. J.B. McLachlan Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection Nat. Immunol. 4 2003 1199 1205
36. L.C. Tetlow, and D.E. Woolley Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies Ann. Rheum. Dis. 54 1995 896 903
37. H. Ji Genetic influences on the end-stage effector phase of arthritis J. Exp. Med. 194 2001 321 330
38. H. Ji Critical roles for interleukin 1 and tumor necrosis factor α in antibody-induced arthritis J. Exp. Med. 196 2002 77 85
39. D.M. Lee Mast cells: a cellular link between autoantibodies and inflammatory arthritis Science 297 2002 1689 1692
40. Y. Nishida Different distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel disease Hepatogastroenterology 49 2002 678 682
41. I. Lilja Tumor necrosis factor-α in ileal mast cells in patients with Crohn's disease Digestion 61 2000 68 76
42. C. Benoist, and D. Mathis Mast cells in autoimmune disease Nature 420 2002 875 878
43. C.E. Demeure Anopheles mosquito bites activate cutaneous mast cells leading to a local inflammatory response and lymph node hyperplasia J. Immunol. 174 2005 3932 3940
44. S.K. Bauman Effects of tumor necrosis factor α on dendritic cell accumulation in lymph nodes draining the immunization site and the impact on the anticryptococcal cell-mediated immune response Infect. Immun. 71 2003 68 74
45. M. Pasparakis Immune and inflammatory responses in TNF α-deficient mice: a critical requirement for TNF α in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response J. Exp. Med. 184 1996 1397 1411
46. H. Korner Distinct roles for lymphotoxin-α and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue Eur. J. Immunol. 27 1997 2600 2609
47. I.K. Campbell Severe inflammatory arthritis and lymphadenopathy in the absence of TNF J. Clin. Invest. 107 2001 1519 1527
48. B. Scallon Binding and functional comparisons of two types of tumor necrosis factor antagonists J. Pharmacol. Exp. Ther. 301 2002 418 426
49. B.J. Scallon Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions Cytokine 7 1995 251 259